Details of the Drug

General Information of Drug (ID: DMPLQ1V)

Drug Name
IFX-1
Synonyms IFX-1 mab
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [1]
Hidradenitis suppurativa ED92.0 Phase 2 [2]
Therapeutic Class
Antiviral Agents
Drug Type
Monoclonal antibody
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 672.9
Logarithm of the Partition Coefficient (xlogp) 9.3
Rotatable Bond Count (rotbonds) 13
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C43H60O6
IUPAC Name
[(1R,3R)-4-[(15Z,17E)-16-formyl-18-(4-hydroxy-2,2,6,6-tetramethylcyclohexyl)-3,7,12-trimethyl-14-oxooctadeca-2,4,6,8,10,12,15,17-octaenylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl] acetate
Canonical SMILES
CC(=CC=CC(=CC=C1[C@](C[C@@H](CC1(C)C)OC(=O)C)(C)O)C)C=CC=CC(=CC(=O)/C=C(/C=C/C2C(CC(CC2(C)C)O)(C)C)\\C=O)C
InChI
InChI=1S/C43H60O6/c1-30(17-14-18-31(2)19-21-39-42(9,10)27-37(49-33(4)45)28-43(39,11)48)15-12-13-16-32(3)23-35(46)24-34(29-44)20-22-38-40(5,6)25-36(47)26-41(38,7)8/h12-24,29,36-38,47-48H,25-28H2,1-11H3/b15-12?,16-13?,18-14?,22-20+,30-17?,31-19?,32-23?,34-24-,39-21?/t36?,37-,38?,43-/m1/s1
InChIKey
XZAPEHKCHWMSPW-MTALQEDYSA-N
Cross-matching ID
PubChem CID
137254326
TTD ID
D06ALE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN complement C5 alpha (C5A) TTRJ91Q CO5_HUMAN (678-1676) Inhibitor [3]
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Coronavirus Disease 2019 (COVID-19)
ICD Disease Classification 1D6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04333420) Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology